GlaucomaNCT07853469
Optical Coherence Tomography Findings Associated With the Glaucoma-periodontitis Stage
An observational study of Glaucoma and GLAUCOMA 1, OPEN ANGLE, D (Disorder), run by Recep Tayyip Erdogan University Training and Research Hospital at 1 site in Turkey (Türkiye).
Trial summary
The aim of this observational study is to investigate the relationship between the stage of periodontal disease and retinal layer thicknesses in glaucoma patients using optical coherence tomography (OCT). Read more about this study
- Who is it for?
- Ages 60 years and olderHealthy volunteers can take part
- Conditions the study is for
- Glaucoma, GLAUCOMA 1, OPEN ANGLE, D (Disorder), Periodontitis
- How many people
- 66 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 6 Oct 2025to 11 May 2026
- How long will I take part?
- 1 Day
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 60 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Individuals over the age of 60 who apply to the Department of Ophthalmology at Recep Tayyip Erdoğan University Faculty of Medicine
Who may be able to join
- Men and women aged 60 years and older
- Systemically healthy individuals
- Patients diagnosed with primary open-angle glaucoma (POAG) according to the European Glaucoma Society (EGS) 2017 classification
Who cannot join
- Presence of autoimmune, osteoporotic, or malignant disease
- Chronic use of immunosuppressive drugs, oral contraceptives, or bisphosphonate therapy
- Pregnancy
- Retinal, optic nerve, or choroidal vascular diseases; cataracts, age-related macular degeneration, uveitis, Behçet's disease, or scleritis
- Previous refractive or intraocular surgery
- Active infectious diseases (e.g., tuberculosis, hepatitis, HIV/AIDS)
- Chronic use of medications that may affect periodontal tissues (e.g., cyclosporine A, phenytoin)
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
Department of Ophthalmology of the Faculty of Medicine of Recep Tayyip Erdogan University
Rize, Rize Province, 53200
About this study
Official title: Evaluation of the Relationship Between the Stage of Periodontal Disease and Retinal Layer Thicknesses in Glaucoma Patients Using Optical Coherence Tomography
The aim of this observational study is to investigate the relationship between the stage of periodontal disease and retinal layer thicknesses in glaucoma patients using optical coherence tomography (OCT). The primary question the study seeks to answer is:
Is there a relationship between the stage of periodontal disease and retinal layer thicknesses in glaucoma patients?
Participants-with and without glaucoma and at various stages of periodontal disease-will undergo periodontal examinations and optical coherence tomography (OCT) assessments to evaluate retinal layer thicknesses.
Read the detailed description
This observational study aims to evaluate the potential relationship between the severity of periodontal disease and retinal layer thickness in patients with glaucoma. Adult individuals with and without a clinically confirmed diagnosis of glaucoma will be included in the study. Periodontal health status will be assessed using standard clinical parameters, such as plaque index, probing pocket depth, clinical attachment loss, and bleeding on probing. Retinal layer thickness will be measured using high-resolution optical coherence tomography (OCT) imaging. The collected data will be analyzed to determine whether the severity of periodontal disease in glaucoma patients is associated with changes in retinal morphology. This study is expected to provide new scientific evidence regarding the potential link between oral inflammatory conditions and ocular health, and to contribute to a better understanding of the possible interaction between periodontal disease and glaucoma.
- Keywords
- periodontitis, glaucoma, optical coherence tomography, retina
- Medical subject headings
- Glaucoma, Periodontitis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Control | Systemically healthy individuals without glaucoma | |
| Normotensive glaucoma | Systemically healthy individuals with primary open-angle glaucoma who have normal intraocular pressure (9-21 mmHg) | |
| Hypertensive glaucoma | Systemically healthy individuals with primary open-angle glaucoma who have high intraocular pressure (≥21 mmHg) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Optical Coherence Tomography (OCT) Measurement
A macular thickness map (ETDRS = Early Treatment Diabetic Retinopathy Study) is examined using OCT, with the center at the fovea centralis. According to the ETDRS map, the central 1 mm represents the fovea, the surrounding 3 mm area represents the inner retinal layers, and the outermost 6 mm area represents the outer retinal layers.
Measured: Day 1
Retinal Layer Thickness
Definition: Retinal thickness is the distance between the internal limiting membrane (ILM) and the retinal pigment epithelium (RPE), measured by optical coherence tomography (OCT). ETDRS Mapping: The macular region is divided into nine sectors based on the ETDRS grid: Central subfield: A 1 mm diameter circle centered on the fovea. Inner ring (parafoveal region): 1-3 mm diameter, divided into superior, inferior, nasal, and temporal quadrants. Outer ring (perifoveal region): 3-6 mm diameter, also divided into four quadrants.
Measured: Day 1
Choroidal Thickness (CSI)
Definition: The choroid is the vascular layer beneath the RPE. Choroidal thickness is the perpendicular distance from Bruch's membrane to the choroid-sclera interface (CSI). Measurement: Typically obtained with enhanced depth imaging OCT (EDI-OCT), mapped according to the ETDRS grid.
Measured: Day 1
Ganglion Cell Layer (GCL) Thickness
Definition: The GCL is composed of the cell bodies of retinal ganglion cells, located between the inner plexiform layer and the retinal nerve fiber layer. Measurement: OCT can quantify GCL alone or GCL + inner plexiform layer (GCL+IPL), usually reported using the ETDRS 9-sector mapping.
Measured: Day 1
Retinal Nerve Fiber Layer (RNFL) Thickness
Definition: The RNFL consists of the unmyelinated axons of ganglion cells, located at the innermost surface of the retina. Measurement: Often assessed in the peripapillary region or in the macular area using ETDRS mapping.
Measured: Day 1
Choroid-Sclera Interface (CSI)
Definition: The CSI is the outer anatomical boundary of the choroid where it transitions into the sclera. Role in Thickness Measurement: Serves as the lower reference point for choroidal thickness measurements (Bruch's membrane to CSI), which can be mapped according to the ETDRS grid.
Measured: Day 1
Secondary outcomes (5)
Clinical Periodontal Parameters (Plaque Index)
Plaque Index (PI) (Silness and Löe, 1964) This index is used to evaluate the amount of dental plaque accumulation on tooth surfaces. Each tooth's four surfaces (buccal, lingual, mesial, distal) are examined using a probe or visually. Each surface is scored from 0 to 3. The average score is calculated for each tooth. The overall plaque index is obtained by averaging the scores from all examined teeth. Score Description 0 No plaque. 1 No visible plaque, but a slight film of plaque is detected when a probe is run along the gingival margin. 2 Visible plaque along the gingival margin, forming a continuous band. 3 Abundant plaque covering the gingival area and extending toward the middle of the tooth surface, including the interproximal spaces.
Measured: Day 1
Clinical Periodontal Parameters (Gingival Index)
The Gingival Index is used to assess the presence and severity of gingival inflammation (gingivitis). Four surfaces of each tooth (buccal, lingual, mesial, distal) are examined visually and with a periodontal probe. The evaluation considers color changes, edema (swelling), tissue consistency, and bleeding on probing. Each surface is scored from 0 to 3. The average score per tooth is calculated, and then the overall average is used to determine the individual's GI score. Score Description 0 Healthy gingiva: normal color and texture, no bleeding 1 Mild inflammation: slight color change and swelling, no bleeding on probing 2 Moderate inflammation: redness, edema, soft tissue, bleeding on probing 3 Severe inflammation: marked redness and swelling, ulceration, possible spontaneous bleeding.
Measured: Day 1
Periodontal Clinical Parametres (Bleeding on Probing Index)
This index is used to assess the presence and severity of gingival inflammation by observing bleeding after gentle pressure is applied to the gingival sulcus using a periodontal probe. A thin periodontal probe is gently inserted into the gingival sulcus with light pressure (approximately 20-25 grams). Bleeding occurring within 10-30 seconds is observed. Each measurement site is recorded as either "bleeding present" or "bleeding absent." Presence of bleeding is an early and sensitive indicator of gingival inflammation. Score Description: 0 No bleeding 1 Bleeding present (mild or severe)
Measured: Day 1
Periodontal Clinical Parametres (Probing Pocket Depth)
Using a Williams periodontal probe, the distance between the gingival margin and the base of the periodontal pocket is measured in millimeters at six sites per tooth: mesiobuccal, midbuccal, distobuccal, mesiolingual, midlingual, and distolingual. All teeth are measured. The values obtained from each site are summed and then divided by the total number of sites measured. This gives the average probing depth for the individual. Measurement Interpretation 1-3 mm Healthy sulcus 4-5 mm Shallow to moderate pocket ≥6 mm Deep periodontal pocket (advanced disease).
Measured: Day 1
Periodontal Clinical Parametres (Clinical Attachment Loss)
Using a Williams periodontal probe, the distance between the enamel-cementum junction and the base of the periodontal pocket is measured in millimeters at six sites per tooth: mesiobuccal, midbuccal, distobuccal, mesiolingual, midlingual, and distolingual. All teeth are measured. The values obtained from each site are summed and then divided by the total number of sites measured. This gives the average probing depth for the individual. CAL Value Interpretation 0-1 mm Healthy / minimal loss 2-3 mm Mild attachment loss 4-5 mm Moderate attachment loss ≥6 mm Severe attachment loss.
Measured: Day 1
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Oct 2026
- Study start6 Oct 2025
- Primary completion6 Apr 2026
- Study completion11 May 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for GlaucomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Enrolment
- 66 participants (actual)
- Target duration
- 1 Day
Sponsor and investigators
- Lead sponsor
- Recep Tayyip Erdogan University Training and Research Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Dilek KARADOĞAN, Recep Tayyip Erdogan University Training and Research Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07853469
- Sponsor's protocol ID
- glaucoma2025/381
- Status last verified
- Sep 2026
- First submitted
- 26 Sep 2026
- Last updated
- 1 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 1 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of the Relationship Between the Stage of Periodontal Disease and Retinal Layer Thicknesses in Glaucoma Patients Using Optical Coherence Tomography
- ClinicalTrials.gov ID
- NCT07853469
- Acronym / sponsor ID
- glaucoma2025/381
- Keywords
- periodontitis, glaucoma, optical coherence tomography, retina
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 66 participants (actual)
- Lead sponsor
- Recep Tayyip Erdogan University Training and Research HospitalUniversity, hospital or other
- Study start
- 6 Oct 2025 (actual)
- Primary completion
- 6 Apr 2026 (actual)
- Study completion
- 11 May 2026 (actual)
- First posted
- 1 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this observational study is to investigate the relationship between the stage of periodontal disease and retinal layer thicknesses in glaucoma patients using optical coherence tomography (OCT). The primary question the study seeks to answer is:
Is there a relationship between the stage of periodontal disease and retinal layer thicknesses in glaucoma patients?
Participants-with and without glaucoma and at various stages of periodontal disease-will undergo periodontal examinations and optical coherence tomography (OCT) assessments to evaluate retinal layer thicknesses.
Detailed description
This observational study aims to evaluate the potential relationship between the severity of periodontal disease and retinal layer thickness in patients with glaucoma. Adult individuals with and without a clinically confirmed diagnosis of glaucoma will be included in the study. Periodontal health status will be assessed using standard clinical parameters, such as plaque index, probing pocket depth, clinical attachment loss, and bleeding on probing. Retinal layer thickness will be measured using high-resolution optical coherence tomography (OCT) imaging. The collected data will be analyzed to determine whether the severity of periodontal disease in glaucoma patients is associated with changes in retinal morphology. This study is expected to provide new scientific evidence regarding the potential link between oral inflammatory conditions and ocular health, and to contribute to a better understanding of the possible interaction between periodontal disease and glaucoma.
Study design
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Target follow-up
- 1 Day
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Control | – | –Systemically healthy individuals without glaucoma |
| Normotensive glaucoma | – | –Systemically healthy individuals with primary open-angle glaucoma who have normal intraocular pressure (9-21 mmHg) |
| Hypertensive glaucoma | – | –Systemically healthy individuals with primary open-angle glaucoma who have high intraocular pressure (≥21 mmHg) |
Who may qualify
- Ages
- 60 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Individuals over the age of 60 who apply to the Department of Ophthalmology at Recep Tayyip Erdoğan University Faculty of Medicine
Key inclusion criteria (3 listed)
- Men and women aged 60 years and older
- Systemically healthy individuals
- Patients diagnosed with primary open-angle glaucoma (POAG) according to the European Glaucoma Society (EGS) 2017 classification
Key exclusion criteria (7 listed)
- Presence of autoimmune, osteoporotic, or malignant disease
- Chronic use of immunosuppressive drugs, oral contraceptives, or bisphosphonate therapy
- Pregnancy
- Retinal, optic nerve, or choroidal vascular diseases; cataracts, age-related macular degeneration, uveitis, Behçet's disease, or scleritis
- Previous refractive or intraocular surgery
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Optical Coherence Tomography (OCT) Measurement
Time frame: Day 1
A macular thickness map (ETDRS = Early Treatment Diabetic Retinopathy Study) is examined using OCT, with the center at the fovea centralis. According to the ETDRS map, the central 1 mm represents the fovea, the surrounding 3 mm area represents the inner retinal layers, and the outermost 6 mm area represents the outer retinal layers.
Retinal Layer Thickness
Time frame: Day 1
Definition: Retinal thickness is the distance between the internal limiting membrane (ILM) and the retinal pigment epithelium (RPE), measured by optical coherence tomography (OCT). ETDRS Mapping: The macular region is divided into nine sectors based on the ETDRS grid: Central subfield: A 1 mm diameter circle centered on the fovea. Inner ring (parafoveal region): 1-3 mm diameter, divided into superior, inferior, nasal, and temporal quadrants. Outer ring (perifoveal region): 3-6 mm diameter, also divided into four quadrants.
Choroidal Thickness (CSI)
Time frame: Day 1
Definition: The choroid is the vascular layer beneath the RPE. Choroidal thickness is the perpendicular distance from Bruch's membrane to the choroid-sclera interface (CSI). Measurement: Typically obtained with enhanced depth imaging OCT (EDI-OCT), mapped according to the ETDRS grid.
Ganglion Cell Layer (GCL) Thickness
Time frame: Day 1
Definition: The GCL is composed of the cell bodies of retinal ganglion cells, located between the inner plexiform layer and the retinal nerve fiber layer. Measurement: OCT can quantify GCL alone or GCL + inner plexiform layer (GCL+IPL), usually reported using the ETDRS 9-sector mapping.
Retinal Nerve Fiber Layer (RNFL) Thickness
Time frame: Day 1
Definition: The RNFL consists of the unmyelinated axons of ganglion cells, located at the innermost surface of the retina. Measurement: Often assessed in the peripapillary region or in the macular area using ETDRS mapping.
Choroid-Sclera Interface (CSI)
Time frame: Day 1
Definition: The CSI is the outer anatomical boundary of the choroid where it transitions into the sclera. Role in Thickness Measurement: Serves as the lower reference point for choroidal thickness measurements (Bruch's membrane to CSI), which can be mapped according to the ETDRS grid.
5 secondary outcomes
Clinical Periodontal Parameters (Plaque Index)
Time frame: Day 1
Clinical Periodontal Parameters (Gingival Index)
Time frame: Day 1
Periodontal Clinical Parametres (Bleeding on Probing Index)
Time frame: Day 1
Periodontal Clinical Parametres (Probing Pocket Depth)
Time frame: Day 1
Periodontal Clinical Parametres (Clinical Attachment Loss)
Time frame: Day 1
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for Glaucoma
Recruiting
Implementing AI-based Glaucoma Screening Within Federally Qualified Health Centers
Glaucoma, Ocular Hypertension
Not yet recruiting
AI-Assisted vs Conventional Teleglaucoma Referral
Glaucoma
Recruiting
Brain Stimulation Effects on Orientation and Mobility Skills in Adults With Vision Impairment
Retinitis Pigmentosa (RP), Rod Cone Dystrophy
Recruiting
Automated Applanation Tonometry - Updated
Glaucoma, Glaucoma, Suspect
RecruitingPhase 2
A Phase 2a Study Comparing the Efficacy, Safety and Tolerability of Pregabalin Eye Drops Comparing With Timolol Eye Drops in Adults With Glaucoma or High Eye Pressure.
Primary Open - Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Glaucoma and GLAUCOMA 1, OPEN ANGLE, D (Disorder), run by Recep Tayyip Erdogan University Training and Research Hospital at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 1 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Optical Coherence Tomography (OCT) Measurement (time frame: Day 1). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Oct 2026.